South Staffordshire Joint FormularyCannock Chase Clinical Commissioning Group East Staffordshire Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group
Formulary Chapter 2: Cardiovascular system - Full Chapter
02.09
Antiplatelet drugs
Aspirin
Formulary
Aspirin Dispersible Tablet 75mg
Use of low dose aspirin for the primary prevention of heart attacks and strokes in people without cardiovascular disease including diabetic patients is no longer recommended as the increased risk of bleeding outweighs any vascular benefits.
Prescribing of antiplatelets for secondary prevention should be in line with NICE Guidelines.
Patients with mild to moderate dyspeptic symptoms taking aspirin should be prescribed a PPI or H2 antagonist before switching to clopidogrel (which may also cause gastro-intestinal adverse effects).
The MHRA has updated its advice on the interaction between PPI's and clopidogrel. It now recommends that use of either omeprazole or esomeprazole with clopidogrel should be discouraged. This does not include lansoprazole.
Not Recommended by NICE for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platlet therapy
Dipyridamole M/R Capsule 200mg Dipyridamole Oral Suspension 50mg/5ml SF
There is a difference in indication between the modified-release preparation of dipyridamole and the standard-release tablets and liquid.
National recommendations for secondary prevention of occlusive vascular events recommend the use of modified-release dipyridamole, according to the licensed indications.
combination product no longer available has been discontinued
Clopidogrel (Grepid®)
Non Formulary
Clopidogrel (Plavix®)
Non Formulary
75mg and 300mg tablets
Prescribe generically
Dipyridamole (Persantin®)
Non Formulary
Dipyridamole (Persantin® Retard)
Non Formulary
Key
Notes
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Restricted Drug
Unlicensed
Display tracking information
Link to adult BNF
Link to children's BNF
Link to SPCs
Scottish Medicines Consortium
Cytotoxic Drug
Controlled Drug
High Cost Medicine
Cancer Drugs Fund
NHS England
Homecare
CCG
Traffic Light Status Information
Status
Description
Drugs which require special consideration. These are drugs for Consultant Prescribing ONLY. They should not be prescribed in Primary Care.
Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care. For some drugs there may be a Ricad in place to aid the transition to primary care.
Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care but also require and ESCA (Shared Care Agreement)
Suitable first-line drugs for implementation in Primary Care